(Q51961246)

19 April 2018

title

A mathematical model to estimate global hepatitis B disease burden and vaccination impact. (English)

1 reference

19 April 2018

1 reference

1 reference

Susan T Goldstein

1 reference

19 April 2018

Fangjun Zhou

1 reference

19 April 2018

Stephen C Hadler

1 reference

19 April 2018

Beth P Bell

1 reference

19 April 2018

Eric E Mast

1 reference

19 April 2018

Harold S Margolis

1 reference

19 April 2018

publication date

25 October 2005

1 reference

19 April 2018

International Journal of Epidemiology

published in

1 reference

19 April 2018

volume

1 reference

19 April 2018

issue

1 reference

19 April 2018

page(s)

1329-1339

1 reference

19 April 2018

Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).

cites work

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Risks of chronicity following acute hepatitis B virus infection: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

HBeAg and anti-hbe detection by radioimmunoassay: Correlation with vertical transmission of hepatitis B virus in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Vertical Transmission of Hepatitis B Antigen in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Incidence of hepatitis B virus infections in preschool children in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Incidence of hepatitis among students at a university in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Factors relating to transmission of viral hepatitis in a United States military population stationed in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Severe viral hepatitis type B in infancy;

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Persistent hepatitis B virus infection and hepatoma in The Gambia, west Africa. A case-control study of 140 adults and their 603 family contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Hepatitis B vaccine in the Gambian Expanded Programme on Immunization: factors influencing antibody response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Are booster immunisations needed for lifelong hepatitis B immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

21 January 2018

Review: hepatitis delta

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Herd immunity: history, theory, practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYI206

21 January 2018

Identifiers

DOI

10.1093/IJE/DYI206

1 reference

19 April 2018

1 reference

19 April 2018